azathioprine has been researched along with Rheumatic Diseases in 62 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Rheumatic Diseases: Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To discuss the relationship between the genotype of thiopurine methyltransferase (TPMT) and azathioprine tolerance in the patients with rheumatic diseases." | 7.74 | [Association between metabolic enzyme genotype of azathioprine and drug tolerance in patients with rheumatic diseases]. ( Huang, M; Li, H; Liang, LQ; Wang, YX; Yang, XY; Zhan, ZP, 2007) |
| "We report 14 cases of secondary myelodysplastic syndromes (sMDS) following treatment with azathioprine for non-malignant disorders." | 7.73 | Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. ( Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Knipp, S; Richter, J, 2005) |
| " Methotrexate, azathioprine, mycophenolate mofetil, cyclosporin cyclophosphamide, chlorambucil, and other related drugs have potential benefits in the treatment of severe and/or recalcitrant rheumatic skin diseases." | 4.81 | Immunosuppressive and cytotoxic drugs in the treatment of rheumatic skin disorders. ( Callen, JP, 2001) |
| "Azathioprine is a useful immunosuppressive agent in Beçhet's disease." | 3.77 | Immunosuppressive drug therapy for rheumatic disease. ( Bayliss, GE; McCune, WJ, 1991) |
| "To discuss the relationship between the genotype of thiopurine methyltransferase (TPMT) and azathioprine tolerance in the patients with rheumatic diseases." | 3.74 | [Association between metabolic enzyme genotype of azathioprine and drug tolerance in patients with rheumatic diseases]. ( Huang, M; Li, H; Liang, LQ; Wang, YX; Yang, XY; Zhan, ZP, 2007) |
| "We report 14 cases of secondary myelodysplastic syndromes (sMDS) following treatment with azathioprine for non-malignant disorders." | 3.73 | Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. ( Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Knipp, S; Richter, J, 2005) |
| "We describe a 67-year-old white man with Wegener's granulomatosis who was treated with cyclophosphamide, then with azathioprine, and who subsequently developed cytomegalovirus retinitis." | 3.67 | Cytomegalovirus retinitis in rheumatic disease: a case report. ( Finan, MJ; Pressly, T; Roberts, R; Winkler, A, 1987) |
| " During treatment with the basic drugs: gold, D-penicillamine and chloroquine, pregnancy should be avoided." | 3.65 | [Problems of rheumatic therapy in pregnancy (author's transl)]. ( Bischof, P, 1976) |
| " In IBD, conventional weight-based dosing with thiopurines leads to an inadequate response in many patients." | 2.50 | The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders. ( Friedman, AB; Gibson, PR; Sparrow, MP, 2014) |
| " TB risk was higher when anti-TNF agents were combined with methotrexate or azathioprine as compared with either controls (24/4241 versus 0/4673; OR 54; 95% CI 5." | 2.50 | Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. ( Armuzzi, A; Bruzzese, V; Diamanti, AP; Gatta, L; Hassan, C; Laganà, B; Lorenzetti, R; Migliore, A; Ridola, L; Zullo, A, 2014) |
| "Azathioprine is a valuable alternative to slow-acting antirheumatic drugs in older patients with rheumatoid arthritis." | 2.38 | Azathioprine, cyclophosphamide and chlorambucil. ( Bacon, PA; Luqmani, RA; Palmer, RG, 1990) |
| "Infection and disease exacerbation are the leading reasons for ICU admission in systemic rheumatic diseases." | 1.72 | Determination of the main causes, outcome, and prognostic factors of patients with rheumatologic diseases admitted to the medical intensive care unit in Southern Iran. ( Arjmand, M; Fallahi, MJ; Shahriarirad, R; Shenavandeh, S, 2022) |
| "As sarcoidosis is a mimicking disease, a good differential diagnosis should be made to avoid misdiagnosis and in order not to be late in diagnosis and treatment." | 1.72 | Perspective of sarcoidosis in terms of rheumatology: a single-center rheumatology clinic experience. ( Duruöz, MT; Esen, İ; Gezer, HH; Karabulut, Y; Öz, N, 2022) |
| "Short episodes of corticosteroids seem to be safe in HBV carriers, even in the presence of DMARDs, but lamivudine prophylaxis should be considered for patients exposed to biologicals or cyclophosphamide." | 1.43 | Safety of Corticosteroid Treatment in Rheumatologic Patients With Markers of Hepatitis B Viral Infection: Pilot Evaluation Study. ( Balbir-Gurman, A; Braun, M; Braun-Moscovici, Y; Markovits, D; Nahir, MA; Saadi, T, 2016) |
| "Azathioprine (AZA) is a commonly used drug for the management of various rheumatologic disorders." | 1.36 | Outcome of patients on azathioprine: a need for a better pre-treatment assessment and dosing guideline. ( Gow, PJ; Jabin, D; Kumar, S, 2010) |
| " Polymerase chain reaction (PCR) tests provide a sensitive, specific means of prospectively identifying these patients before AZA therapy and minimizing toxicity through dosage reduction." | 1.31 | Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. ( Anis, AH; Esdaile, JM; Marra, CA, 2002) |
| "In addition to any increased risk of malignancy that may be conferred by individual rheumatic diseases, there is a further risk of specific types of malignancy that is related to the duration of exposure to immunosuppressive drugs." | 1.30 | Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. ( Asten, P; Barrett, J; Symmons, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (33.87) | 18.7374 |
| 1990's | 12 (19.35) | 18.2507 |
| 2000's | 15 (24.19) | 29.6817 |
| 2010's | 10 (16.13) | 24.3611 |
| 2020's | 4 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Arjmand, M | 1 |
| Shahriarirad, R | 1 |
| Shenavandeh, S | 1 |
| Fallahi, MJ | 1 |
| Karabulut, Y | 1 |
| Öz, N | 1 |
| Gezer, HH | 1 |
| Esen, İ | 1 |
| Duruöz, MT | 1 |
| Yang, J | 1 |
| Wang, P | 1 |
| Qin, Z | 1 |
| Jia, M | 1 |
| Zhang, C | 1 |
| Tian, X | 1 |
| Zheng, Y | 1 |
| Zhang, A | 1 |
| Zhang, X | 1 |
| Liu, S | 1 |
| Broen, JCA | 1 |
| van Laar, JM | 1 |
| Su, SS | 1 |
| Lin, YF | 1 |
| Zhou, H | 1 |
| Polk, BI | 1 |
| Becker, ML | 2 |
| Xuan, D | 1 |
| Yu, Y | 1 |
| Shao, L | 1 |
| Wang, J | 1 |
| Zhang, W | 1 |
| Zou, H | 1 |
| Friedman, AB | 1 |
| Sparrow, MP | 1 |
| Gibson, PR | 1 |
| Lorenzetti, R | 1 |
| Zullo, A | 1 |
| Ridola, L | 1 |
| Diamanti, AP | 1 |
| Laganà, B | 1 |
| Gatta, L | 1 |
| Migliore, A | 1 |
| Armuzzi, A | 1 |
| Hassan, C | 1 |
| Bruzzese, V | 1 |
| Braun-Moscovici, Y | 1 |
| Braun, M | 1 |
| Saadi, T | 1 |
| Markovits, D | 1 |
| Nahir, MA | 1 |
| Balbir-Gurman, A | 1 |
| Mimori, T | 1 |
| Jabin, D | 1 |
| Kumar, S | 1 |
| Gow, PJ | 1 |
| Matsumoto, I | 1 |
| Miller, AV | 1 |
| Ranatunga, SK | 1 |
| Siva, C | 1 |
| Yokoyama, WM | 1 |
| McLeod, HL | 3 |
| Seidman, EG | 1 |
| Furst, DE | 1 |
| Marra, CA | 1 |
| Esdaile, JM | 1 |
| Anis, AH | 1 |
| Mayer, DF | 1 |
| Kushwaha, SS | 1 |
| Mitnick, H | 1 |
| Jacobowitz, G | 1 |
| Krinsky, G | 1 |
| Eberle, M | 1 |
| Rosenzweig, B | 1 |
| Willis, D | 1 |
| Rockman, C | 1 |
| Riles, T | 1 |
| Knipp, S | 1 |
| Hildebrandt, B | 1 |
| Richter, J | 1 |
| Haas, R | 1 |
| Germing, U | 1 |
| Gattermann, N | 1 |
| Zhan, ZP | 2 |
| Yang, XY | 2 |
| Liang, LQ | 2 |
| Wang, YX | 2 |
| Huang, M | 2 |
| Lian, F | 1 |
| Payne, K | 1 |
| Newman, W | 1 |
| Fargher, E | 1 |
| Tricker, K | 1 |
| Bruce, IN | 1 |
| Ollier, WE | 1 |
| Glück, T | 1 |
| Müller-Ladner, U | 1 |
| Li, H | 1 |
| Vroom, F | 1 |
| van Roon, EN | 1 |
| van den Berg, PB | 1 |
| Brouwers, JR | 1 |
| de Jong-van den Berg, LT | 1 |
| Turner, RA | 1 |
| Johnson, JA | 1 |
| Semble, EL | 1 |
| Jones, SM | 1 |
| Calin, A | 1 |
| Solinger, AM | 1 |
| Hess, EV | 1 |
| Bermas, BL | 1 |
| Hill, JA | 1 |
| Ramsey-Goldman, R | 1 |
| Schilling, E | 1 |
| McCune, J | 1 |
| Singer, NG | 1 |
| Black, AJ | 1 |
| Capell, HA | 1 |
| Powrie, RH | 1 |
| Matowe, LK | 1 |
| Pritchard, SC | 1 |
| Collie-Duguid, ES | 1 |
| Reid, DM | 1 |
| Asten, P | 1 |
| Barrett, J | 1 |
| Symmons, D | 1 |
| Ishioka, S | 1 |
| Hiyama, K | 1 |
| Sato, H | 1 |
| Yamanishi, Y | 1 |
| Kumagai, K | 1 |
| Maeda, H | 1 |
| Yamakido, M | 1 |
| Ichikawa, Y | 1 |
| Pickenpack, A | 1 |
| Straub, RH | 1 |
| Distler, O | 1 |
| Hammond, A | 1 |
| Oellerich, M | 1 |
| Schölmerich, J | 1 |
| Lang, B | 1 |
| Schütz, E | 1 |
| Balakrishnan, C | 1 |
| Mangat, G | 1 |
| Kalke, S | 1 |
| Desai, D | 1 |
| Joshi, A | 1 |
| Deshpande, RB | 1 |
| Joshi, VR | 1 |
| Callen, JP | 1 |
| Pirofsky, B | 1 |
| Bardana, EJ | 1 |
| Faust-Tinnefeldt, G | 1 |
| Brinkrolf, H | 1 |
| Mathies, H | 1 |
| Evens, RP | 1 |
| Bischof, P | 1 |
| James, DG | 1 |
| Friedmann, AI | 1 |
| Graham, E | 1 |
| McCune, WJ | 2 |
| Friedman, AW | 1 |
| Bayliss, GE | 1 |
| Luqmani, RA | 1 |
| Palmer, RG | 1 |
| Bacon, PA | 1 |
| Clements, PJ | 1 |
| Davis, J | 1 |
| O'Callaghan, JW | 1 |
| Brooks, PM | 1 |
| Winkler, A | 1 |
| Finan, MJ | 1 |
| Pressly, T | 1 |
| Roberts, R | 1 |
| Dugowson, CE | 1 |
| Gilliland, BC | 1 |
| Ostensen, M | 1 |
| Husby, G | 1 |
| Tsokos, GC | 1 |
| Balow, JE | 1 |
| Huskisson, EC | 1 |
| Meadow, SR | 1 |
| Glasgow, EF | 1 |
| White, RH | 1 |
| Moncrieff, MW | 1 |
| Cameron, JS | 1 |
| Ogg, CS | 1 |
| Klein, G | 1 |
| Fellner, S | 1 |
| Fellner, R | 1 |
| Rothermich, NO | 1 |
| Mayr, E | 1 |
| Kahn, MF | 1 |
| Krampac, I | 1 |
| Pavkovceková, O | 1 |
| Démant, F | 1 |
| Tischler, V | 1 |
| Mydlík, M | 1 |
| Jurkovic, I | 1 |
| Prekop, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| he Efficacy and Safety of Combining Mycophenolate Mofetil With Methimazole on Remission of Newly Diagnosis Graves' Disease (3M-RGD Trial): an Open-label, Randomized Trial[NCT06068179] | Phase 2/Phase 3 | 205 participants (Anticipated) | Interventional | 2023-10-08 | Not yet recruiting | ||
| Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical Trial[NCT05916781] | Phase 4 | 220 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 reviews available for azathioprine and Rheumatic Diseases
| Article | Year |
|---|---|
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.
Topics: Antirheumatic Agents; Azathioprine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunosupp | 2020 |
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.
Topics: Antirheumatic Agents; Azathioprine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunosupp | 2020 |
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.
Topics: Antirheumatic Agents; Azathioprine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunosupp | 2020 |
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.
Topics: Antirheumatic Agents; Azathioprine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunosupp | 2020 |
Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy.
Topics: Antirheumatic Agents; Azathioprine; Biological Products; Biomarkers; Child; Genome, Human; Genotype; | 2013 |
Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Arthritis, Rheumatoid; Azathioprine; Cohort Studies; Derm | 2014 |
The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders.
Topics: Animals; Anti-Inflammatory Agents; Azathioprine; Drug Interactions; Gastrointestinal Agents; Humans; | 2014 |
Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Certolizumab Pe | 2014 |
[Immunosuppressants].
Topics: Azathioprine; Calcineurin Inhibitors; Collagen Diseases; Cyclophosphamide; Cyclosporine; Humans; Imm | 2009 |
[Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 4. Azathioprine].
Topics: Azathioprine; Collagen Diseases; Humans; Immunosuppressive Agents; Rheumatic Diseases | 2011 |
Immunotherapies in rheumatologic disorders.
Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monocl | 2012 |
Pharmacogenomics in pediatric rheumatology.
Topics: Antimetabolites; Antirheumatic Agents; Azathioprine; Biological Products; Child; Humans; Methotrexat | 2012 |
Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field.
Topics: Analgesics, Opioid; Antirheumatic Agents; Azathioprine; Drug Design; Drug Interactions; Drug-Related | 2002 |
Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine.
Topics: Antirheumatic Agents; Azathioprine; Drug Monitoring; Genotype; Humans; Methyltransferases; Pharmacog | 2002 |
Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases.
Topics: Autoimmune Diseases; Azathioprine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 2003 |
[Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Azathioprine; Biological Pro | 2007 |
Effects of immunosuppressive drugs during pregnancy.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Animals; Azathioprine; Chlorambucil; Cyclophos | 1995 |
Immunosuppressive drug use during pregnancy.
Topics: Adrenal Cortex Hormones; Animals; Azathioprine; Chlorambucil; Cyclophosphamide; Cyclosporine; Female | 1997 |
Immunosuppressive drug treatment.
Topics: Azathioprine; Cyclophosphamide; Humans; Immunization; Immunocompromised Host; Immunosuppressive Agen | 1997 |
Immunosuppressive and cytotoxic drugs in the treatment of rheumatic skin disorders.
Topics: Adult; Alkylating Agents; Antimetabolites; Azathioprine; Child; Chlorambucil; Cladribine; Cyclophosp | 2001 |
Immunosuppressive therapy in rheumatic disease.
Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Dermatomyositis; Gr | 1977 |
Immunosuppressive drug therapy for rheumatic disease.
Topics: Azathioprine; Chlorambucil; Cyclosporine; Humans; Immunosuppressive Agents; Rheumatic Diseases | 1992 |
Immunosuppressive drug therapy for rheumatic disease.
Topics: Azathioprine; Cyclophosphamide; Cyclosporins; Humans; Immunosuppressive Agents; Mechlorethamine; Rhe | 1991 |
Azathioprine, cyclophosphamide and chlorambucil.
Topics: Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Connective Tissue Diseases; Cyclophosphamide; Hum | 1990 |
Cytotoxic drugs: their clinical application to the rheumatic diseases.
Topics: Arthritis; Arthritis, Rheumatoid; Azathioprine; Behcet Syndrome; Bone Marrow; Cell Division; Chemica | 1986 |
Disease-modifying agents and immunosuppressive drugs in the elderly.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Antimalarials; Azathioprine; Cyclophosphami | 1986 |
Management of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Azathioprine; Chloroquine; Cyc | 1986 |
Antirheumatic drug treatment during pregnancy and lactation.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Azathioprine; Chloroquine; Cyc | 1985 |
Immunosuppressive agents and plasmapheresis in immunological disorders.
Topics: Animals; Antigen-Antibody Complex; Autoantibodies; Azathioprine; Cyclophosphamide; Glucocorticoids; | 1985 |
An updated look at antirheumatic drugs.
Topics: Allopurinol; Anti-Inflammatory Agents; Arthritis; Azathioprine; Chloroquine; Cyclophosphamide; Gluco | 1967 |
[Antirheumatics. 40].
Topics: Anti-Inflammatory Agents; Antilymphocyte Serum; Azathioprine; Chlorambucil; Female; Humans; Immunosu | 1969 |
[The immunodepressive agents. II. Immunodepressive agents in rheumatic diseases].
Topics: Azathioprine; Chlorambucil; Humans; Immunosuppressive Agents; Rheumatic Diseases; Thiotepa | 1967 |
5 trials available for azathioprine and Rheumatic Diseases
| Article | Year |
|---|---|
Safety and efficacy of an intravenous loading dose of azathioprine for treatment of non-TPMT-deficient patients with rheumatic diseases.
Topics: Antirheumatic Agents; Azathioprine; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2000 |
Immunosuppressive therapy in rheumatic disease.
Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Dermatomyositis; Gr | 1977 |
[Azathioprine in long-term therapy of inflammatory rheumatic diseases. Variability of laboratory chemical parameters].
Topics: Alkaline Phosphatase; Azathioprine; Blood Cell Count; Blood Sedimentation; gamma-Glutamyltransferase | 1978 |
Immunosuppressive drug therapy for rheumatic disease.
Topics: Azathioprine; Cyclophosphamide; Cyclosporins; Humans; Immunosuppressive Agents; Mechlorethamine; Rhe | 1991 |
[Indomethacin in rheumatic diseases with special reference to ophthalmologic studies].
Topics: Allopurinol; Arthritis, Rheumatoid; Azathioprine; Blood Cells; Capsules; Clinical Trials as Topic; E | 1972 |
30 other studies available for azathioprine and Rheumatic Diseases
| Article | Year |
|---|---|
Determination of the main causes, outcome, and prognostic factors of patients with rheumatologic diseases admitted to the medical intensive care unit in Southern Iran.
Topics: Arthritis, Rheumatoid; Azathioprine; Disease Progression; Dyspnea; Female; Hospital Mortality; Human | 2022 |
Perspective of sarcoidosis in terms of rheumatology: a single-center rheumatology clinic experience.
Topics: Adrenal Cortex Hormones; Ambulatory Care Facilities; Anti-Inflammatory Agents, Non-Steroidal; Arthri | 2022 |
Topics: Adolescent; Adult; Aged; Alleles; Asian People; Azathioprine; Biomarkers; Child; Female; Genetic Pre | 2019 |
Association of thiopurine S-methyltransferase and NUDT15 polymorphisms with azathioprine-induced myelotoxicity in Chinese patients with rheumatological disease.
Topics: Adolescent; Adult; Asian People; Azathioprine; Humans; Immunosuppressive Agents; Methyltransferases; | 2020 |
Safety of Corticosteroid Treatment in Rheumatologic Patients With Markers of Hepatitis B Viral Infection: Pilot Evaluation Study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Alanine Transaminase; Antirheumatic Agents; Azathioprine; Cycl | 2016 |
Outcome of patients on azathioprine: a need for a better pre-treatment assessment and dosing guideline.
Topics: Antirheumatic Agents; Azathioprine; Dose-Response Relationship, Drug; Drug Monitoring; Female; Follo | 2010 |
Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Cost-Benefit Analysis; Decision Support T | 2002 |
Periaortitis: gadolinium-enhanced magnetic resonance imaging and response to therapy in four patients.
Topics: Aged; Anti-Inflammatory Agents; Arteriosclerosis; Azathioprine; Contrast Media; Female; Gadolinium D | 2004 |
Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azathioprine; Cell Transformation, Neoplastic; | 2005 |
[The profile and clinical significance of azathioprine metabolic enzymes activity in rheumatological patients].
Topics: Adolescent; Adult; Azathioprine; Bone Marrow; Drug Tolerance; Erythrocytes; Female; Follow-Up Studie | 2006 |
TPMT testing in rheumatology: any better than routine monitoring?
Topics: Antirheumatic Agents; Azathioprine; Drug Administration Schedule; Drug Monitoring; Humans; Immunosup | 2007 |
[Association between metabolic enzyme genotype of azathioprine and drug tolerance in patients with rheumatic diseases].
Topics: Adolescent; Adult; Analysis of Variance; Azathioprine; Drug Resistance; Female; Gene Frequency; Geno | 2007 |
Prescribing of sulfasalazine, azathioprine and methotrexate round pregnancy--a descriptive study.
Topics: Antirheumatic Agents; Azathioprine; Databases, Factual; Drug Prescriptions; Drug Therapy, Combinatio | 2008 |
Antirheumatic drug effects on neutrophil response to chemotactic factors: a comparison of analytical techniques.
Topics: Aspirin; Azathioprine; Chemotactic Factors; Chemotaxis, Leukocyte; Dose-Response Relationship, Drug; | 1983 |
The monitoring of patients on disease-modifying antirheumatoid drugs.
Topics: Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Humans; Methotrexate; Rheumatic Diseases | 1993 |
Rheumatic diseases and AIDS--is the association real?
Topics: Acquired Immunodeficiency Syndrome; Adult; Azathioprine; Female; Humans; Male; Muscular Diseases; Pa | 1993 |
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine.
Topics: Adult; Antirheumatic Agents; Azathioprine; Female; Hematologic Diseases; Heterozygote; Humans; Male; | 1998 |
Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases.
Topics: Aged; Aged, 80 and over; Azathioprine; Europe; Female; Follow-Up Studies; Humans; Immunosuppressive | 1999 |
Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese.
Topics: Azathioprine; Genotype; Humans; Immunosuppressive Agents; Japan; Methyltransferases; Mutation; Rheum | 1999 |
Single nucleotide polymorphism to disclose severe side-effects or proper dosage for each patient.
Topics: Azathioprine; Humans; Immunosuppressive Agents; Methyltransferases; Mutation; Polymorphism, Single N | 2000 |
The spectrum of chronic autoimmune hepatitis.
Topics: Adolescent; Adult; Autoantibodies; Azathioprine; Biopsy, Needle; Chronic Disease; Female; Hepatitis | 1998 |
[Azathioprine in rheumatology].
Topics: Arthritis, Rheumatoid; Azathioprine; Chromosome Aberrations; Humans; Immunosuppression Therapy; Lupu | 1979 |
Antirheumatic agents.
Topics: Adrenal Cortex Hormones; Antimalarials; Aspirin; Azathioprine; Chloroquine; Cyclophosphamide; Gold; | 1979 |
[Problems of rheumatic therapy in pregnancy (author's transl)].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Azathioprine; Chloroquine; Female; Fetal Diseases | 1976 |
Uveitis. A series of 368 patients.
Topics: Adolescent; Adult; Aged; Antigen-Antibody Complex; Autoantibodies; Azathioprine; Child; Child, Presc | 1976 |
Cytomegalovirus retinitis in rheumatic disease: a case report.
Topics: Adult; Azathioprine; Cyclophosphamide; Cytomegalovirus Infections; Granulomatosis with Polyangiitis; | 1987 |
Recent drugs and the rheumatic diseases.
Topics: Acetaminophen; Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 1974 |
Schönlein-Henoch nephritis.
Topics: Adolescent; Adrenal Cortex Hormones; Azathioprine; Biopsy; Child; Child, Preschool; Cyclophosphamide | 1972 |
[Positive and negative effects of cytostatic therapy in rheumatic patients].
Topics: Antineoplastic Agents; Azathioprine; Chlorambucil; Cyclophosphamide; Humans; Mercaptopurine; Methotr | 1970 |
[Immunosuppressive therapy of kidney lesio in Schönlein-Henoch purpura].
Topics: Azathioprine; Child; Female; Humans; Immunosuppressive Agents; Kidney Diseases; Male; Purpura; Rheum | 1970 |